2026-07-28
Investment marks the first batch of portfolio companies of Blue Ocean Capital’s Blue Ocean Intelligent Brain Seed Fund and supports Torrey Pines Medicine’s development of TPM004 and its proprietary PepTetris™ peptide discovery platform for obesity, diabetes and other metabolic diseases.
SHENZHEN, China, July 28, 2026 — Blue Ocean Capital today announced its investment in Torrey Pines Medicine (Shenzhen) Ltd., a biotechnology company developing next-generation ultra-long-acting peptide therapeutics for metabolic diseases, as part of Torrey Pines Medicine’s tens-of-millions-of-RMB angel financing round.
The financing was led by Lotus Lake Ventures, with participation from Stars Capital, Tainuo Capital, Blue Ocean Capital and renowned entrepreneur Mr. Yousheng Shen. Torrey Pines Medicine is one of the first batch portfolio companies of Blue Ocean Capital’s Blue Ocean Intelligent Brain Seed Fund. Proceeds from the financing will primarily support Torrey Pines Medicine’s corporate development, accelerate IND filing and Phase I clinical trials for its core pipeline asset, TPM004, and further advance the company’s proprietary PepTetris™ ultra-long-acting peptide technology platform to support the continued development of early-stage R&D pipelines.
"We are deeply grateful for the trust and support from our investors. R&D in metabolic diseases is entering a new era. Significant unmet clinical needs remain regarding patient compliance, enhanced efficacy, and better overall therapeutic experience. At Torrey Pines Medicine, we will continue leveraging our proprietary platform to engineer globally competitive, ultra-long-acting peptide therapeutics that provide convenient and highly effective long-term management solutions for patients." said Dr. Qingsong Zhu, Co-founder and Chief Executive Officer of Torrey Pines Medicine.
Frank Yang, Founding Partner and CEO of Blue Ocean Capital, said, “We remain committed to supporting innovative R&D for novel drugs targeting metabolic diseases across a range of biotechnology approaches. Torrey Pines Medicine’s founding team impressed us with its world-class scientific expertise, extensive entrepreneurial and industry experience, and global perspective. We look forward to seeing the company leverage its proprietary long-acting delivery platform and differentiated products to rapidly advance clinical development, strategic partnerships and product commercialization, ultimately benefiting patients worldwide.”
According to Dr. Weijun Shen, Co-founder and Chief Scientific Officer of Torrey Pines Medicine, the development of truly next-generation peptide therapeutics requires more than simply extending drug half-life. "Developing ultra-long-acting peptide medicines requires a holistic optimization of molecular design, receptor pharmacology, pharmacokinetics, manufacturability, and clinical translatability. Our objective is not simply to prolong circulation time, but to engineer molecules that deliver the optimal balance of efficacy, safety, dosing convenience, and developability.”
Dr. Ning Yan, President of the Shenzhen Medical Academy of Research and Translation (SMART) and Director of Shenzhen Bay Laboratory (SZBL), congratulated the company on completing its angel financing. " We extend our warmest congratulations to Torrey Pines Medicine on the successful completion of its angel financing. As a flagship venture incubated by Shenzhen Bay Laboratory, Torrey Pines Medicine encapsulates the deep integration of foundational research, technological innovation, and industrial translation. We look forward to seeing them leverage their international team and platform advantages to accelerate the translation of original scientific breakthroughs into clinical applications.”
About Torrey Pines Medicine
Torrey Pines Medicine is a pre-clinical-stage biotechnology company incubated by Shenzhen Bay Laboratory, dedicated to developing next-generation ultra-long-acting peptide therapeutics for obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and other chronic metabolic diseases. To address key clinical unmet needs associated with current mainstream weight-loss treatments—including gastrointestinal adverse events, muscle mass loss, poor long-term adherence, and weight regain post-discontinuation—Torrey Pines Medicine is building an end-to-end R&D engine focused on ultra-long-acting peptide novel drugs.
The company's proprietary PepTetris™ platform integrates AI-guided design, innovative molecular engineering, half-life extension, and multi-target synergy. By significantly extending in vivo exposure while maintaining pharmacological potency and minimizing adverse reactions, PepTetris™ enables the efficient development of monthly or longer dosing regimen peptides. Lead asset TPM004 is a next-generation ultra-long-acting amylin/calcitonin dual receptor agonist (DACRA) targeted for key clinical readout data in 2027. Preclinical studies demonstrate TPM004 supports potential monthly subcutaneous administration, exhibits superior weight-loss efficacy, delays weight rebound post-treatment, and possesses high solubility and stability at physiological pH, enabling co-formulation development with various GLP-1 therapeutics.
Torrey Pines Medicine boasts a core leadership team with over 20 years of experience in innovative peptide drug development and commercialization. Team members bring extensive domain expertise from leading global and domestic research institutions and pharmaceutical enterprises, including Insilico Medicine, Novartis GNF, Scripps Research – Calibr, Shenzhen Bay Laboratory, Peking University, and HEC Pharma. The team's comprehensive capabilities span the entire drug discovery and development lifecycle, including target discovery, AI-assisted drug design, drug screening (pharmacology, pharmacokinetics, CMC development), preclinical evaluation, IND regulatory filings, and clinical trial execution, enabling seamless execution from bench to bedside.
